Individualized fracture risk assessment: Progresses and challenges

Current Opinion in Rheumatology

Volumn 25, Issue 4, 2013, Pages 532-541

  Nguyen, Tuan V ^a,b,c   Center, Jacqueline R ^a,b   Eisman, John A ^a,b,d  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ST VINCENT'S CLINIC   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d Notre Dame University   (Australia)

Author keywords

fracture; Fracture Risk Assessment Tool; garvan fracture risk calculator; osteoporosis

Indexed keywords

ALENDRONIC ACID; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; RALOXIFENE; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; FRACTURE; FRACTURE RISK ASSESSMENT TOOL; FRAGILITY FRACTURE; GARVAN FRACTURE RISK CALCULATOR; HIP FRACTURE; HIP SURGERY; HUMAN; MORTALITY; OSTEOPOROSIS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK ASSESSMENT; RISK FACTOR; VALIDATION STUDY;

BIOMEDICAL RESEARCH; BONE DENSITY CONSERVATION AGENTS; HUMANS; OSTEOPOROTIC FRACTURES; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84879885245     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328361ff8c     Document Type: Review

References (69)

1. Nguyen ND, Ahlborg HG, Center JR, et al. Residual lifetime risk of fractures in women and men. J Bone Miner Res 2007; 22:781-788. (Pubitemid 351339737)
2. Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989; 149:2445-2448. (Pubitemid 19283200)
3. Shortt NL, Robinson CM. Mortality after low-energy fractures in patients aged at least 45 years old. J Orthop Trauma 2005; 19:396-400.
4. Randell A, Sambrook PN, Nguyen TV, et al. Direct clinical and welfare costs of osteoporotic fractures in elderly men and women. Osteoporos Int 1995; 5:427-432.
5. Access Economics Pty Ltd. The Burden of Brittle Bones: Costing Osteoporosis in Australia. Canberra, ACT: Access Ecomomics Pty Ltd; 2001.
6. Sanders KM, Seeman E, Ugoni AM, et al. Age- and gender-specific rate of fractures in Australia: a population-based study. Osteoporos Int 1999; 10:240-247. (Pubitemid 29458720)
7. Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009; 301:513-521.
8. Center JR, Bliuc D, Nguyen TV, Eisman JA. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 2007; 297:387-394. (Pubitemid 46155800)
9. Johnell O, Kanis JA, Oden A, et al. Fracture risk following an osteoporotic fracture. Osteoporos Int 2004; 15:175-179. (Pubitemid 38391531)
10. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353:878-882. (Pubitemid 29126875)
11. Bolland MJ,Grey AB, Gamble GD, Reid IR. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 2010; 95:1174-1181.
12. Center JR, Bliuc D, Nguyen ND, et al. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab 2011; 96:1006-1014.
13. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture. N Engl J Med 2007; 357:1799-1809. (Pubitemid 350044800)
14. Beaupre LA, Morrish DW, Hanley DA, et al. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int 2011; 22:983-991.
15. Eisman J, Clapham S, Kehoe L. Osteoporosis prevalence and levels of treatment in primary care: the Australian BoneCare Study. J Bone Miner Res 2004; 19:1969-1975. (Pubitemid 41103411)
16. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312:1254-1259. (Pubitemid 26147662)
17. Nguyen T, Sambrook P, Kelly P, et al. Prediction of osteoporotic fractures by postural instability and bone density. BMJ 1993; 307:1111-1115. (Pubitemid 23313207)
18. Nguyen ND, Eisman JA, Center JR, Nguyen TV. Risk factors for fracture in nonosteoporotic men and women. J Clin Endocrinol Metab 2007; 92:955-962. (Pubitemid 46465669)
19. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359:1761-1767.
20. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332:767-773.
21. Nguyen ND, Frost SA, Center JR, et al. Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int 2007; 18:1109-1117. (Pubitemid 47020008)
22. Nguyen ND, Pongchaiyakul C, Center JR, et al. Identification of high-risk individuals for hip fracture: a 14-year prospective study. J Bone Miner Res 2005; 20:1921-1928. (Pubitemid 41532777)
23. Nguyen ND, Frost SA, Center JR, et al. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 2008; 19:1431-1444.
24. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19:385-397.
25. Collins GS, Mallett S, Altman DG. Predicting risk of osteoporotic and hip fracture in the United Kingdom: prospective independent and external validation of QFractureScores. BMJ 2011; 342:d3651.
26. Harrell FEJ, Califf RM, Pryor DB, et al. Evaluating the yield of medical tests. JAMA 1982; 247:2543-2546. (Pubitemid 12155954)
27. Huntjens KM, Kosar S, van Geel TA, et al. Risk of subsequent fracture and mortality within 5 years after a nonvertebral fracture. Osteoporos Int 2010; 21:2075-2082.
28. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27:157-172; discussion 207-12. (Pubitemid 351193639)
29. Cook NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem 2008; 54:17-23. (Pubitemid 351182592)
30. Sandhu SK, Nguyen ND, Center JR, et al. Prognosis of fracture: evaluation of predictive accuracy of the FRAX algorithm and Garvan nomogram. Osteoporos Int 2010; 21:863-871.
31. Langsetmo L, Nguyen TV, Nguyen ND, et al. Independent external validation of nomograms for predicting risk of low-trauma fracture and hip fracture. CMAJ 2011; 183:E107-E114.
32. Leslie WD, Lix LM, Johansson H, et al. Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res 2010; 25:2350-2358.
33. Leslie WD, Lix LM, Langsetmo L, et al. Construction of a FRAX(R) model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int 2011; 22:817-827.
34. Ensrud KE, Lui LY, Taylor BC, et al. A comparison of prediction models for fractures in older women: is more better? Arch Intern Med 2009; 169:2087-2094.
35. Tamaki J, Iki M, Kadowaki E, et al. Fracture risk prediction using FRAX(R): a 10-year follow-up survey of the Japanese Population-Based Osteoporosis (JPOS) Cohort Study. Osteoporos Int 2011; 22:3037-3045.
36. Azagra R, Roca G, Encabo G, et al. FRAX(R) tool, the WHO algorithm to predict osteoporotic fractures: the first analysis of its discriminative and predictive ability in the Spanish FRIDEX cohort. BMC Musculoskelet Disord 2012; 13:204.
37. van Geel TA, Nguyen ND, Geusens PP, et al. Development of a simple prognostic nomogram for individualising 5-year and 10-year absolute risks of fracture: a population-based prospective study among postmenopausal women. Ann Rheum Dis 2011; 70:92-97.
38. Aubry-Rozier B, Stoll D, Krieg MA, et al. What was your fracture risk evaluated by FRAX(R) the day before your osteoporotic fracture? Clin Rheumatol 2013; 32:219-223.
39. NOF. Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation. Washington DC; 2008.
40. Delmas PD, Rizzoli R, Cooper C, Reginster JY. Treatment of patients with postmenopausal osteoporosis is worthwhile: the position of the International Osteoporosis Foundation. Osteoporos Int 2005; 16:1-5. (Pubitemid 40193213)
41. McCloskey E, Johansson H, Oden A, et al. Efficacy of clodronate on fracture risk in women selected by 10-year fracture probability. J Bone Miner Res 2007; 22:S131.
42. Donaldson MG, Palermo L, Ensrud KE, et al. Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial. J Bone Miner Res 2012; 27:1804-1810.
43. McCloskey EV, Johansson H, Oden A, et al. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 2012; 27:1480-1486.
44. Kanis JA, Johansson H, Oden A, McCloskey EV. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 2009; 44:1049-1054.
45. Kanis JA, Johansson H, Oden A, McCloskey EV. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and nonvertebral fracture in postmenopausal osteoporosis and the interaction with FRAX((R)). Osteoporos Int 2011; 22:2347-2355.
46. Kanis JA, Johansson H, Oden A, McCloskey EV. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 2010; 47:729-735.
47. Tran BN, Nguyen ND, Center JR, et al. Enhancement of absolute fracture risk prognosis with genetic marker: the collagen I alpha 1 gene. Calcif Tissue Int 2009; 85:379-388.
48. Tran BN, Nguyen ND, Nguyen VX, et al. Genetic profiling and individualized prognosis of fracture. J Bone Miner Res 2011; 26:414-419.
49. Zheng HF, Tobias JH, Duncan E, et al. WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS Genet 2012; 8:e1002745.
50. Medina-Gomez C, Kemp JP, Estrada K, et al. Meta-analysis of genome-wide scans for total body BMD in children and adults reveals allelic heterogeneity and age-specific effects at the WNT16 locus. PLoS Genet 2012; 8: e1002718.
51. Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet 2012; 44:491-501.
52. Zheng HF, Spector TD, Richards JB. Insights into the genetics of osteoporosis from recent genome-wide association studies. Expert Rev Mol Med 2011; 13:e28.
53. Duncan EL, Danoy P, Kemp JP, et al. Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. PLoS Genet 2011; 7:e1001372.
54. Karasik D, Dupuis J, Cho K, et al. Refined QTLs of osteoporosis-related traits by linkage analysis with genome-wide SNPs: Framingham SHARe. Bone 2010; 46:1114-1121.
55. Timpson NJ, Tobias JH, Richards JB, et al. Common variants in the region around Osterix are associated with bone mineral density and growth in childhood. Hum Mol Genet 2009; 18:1510-1517.
56. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, et al. New sequence variants associated with bone mineral density. Nat Genet 2009; 41:15-17.
57. Rivadeneira F, Styrkarsdottir U, Estrada K, et al. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet 2009; 41:1199-1206.
58. Richards JB, Kavvoura FK, Rivadeneira F, et al. Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture. Ann Intern Med 2009; 151:528-537.
59. Zhang F, Xiao P, Yang F, et al. A whole genome linkage scan for QTLs underlying peak bone mineral density. Osteoporos Int 2008; 19:303-310. (Pubitemid 351199185)
60. Styrkarsdottir U, Halldorsson BV,Gretarsdottir S, et al. Multiple genetic loci for bone mineral density and fractures. N Engl J Med 2008; 358:2355-2365. (Pubitemid 351749159)
61. Sims AM, Shephard N, Carter K, et al. Genetic analyses in a sample of individuals with high or low BMD shows association with multiple Wnt pathway genes. J Bone Miner Res 2008; 23:499-506. (Pubitemid 351501890)
62. Kaplan S, Garrick BJ. On the quantitative definition of risk. Risk Analysis 1981; 1:11-27. (Pubitemid 12121289)
63. Nau RF. De Finetti was right: probability does not exist. Theory Decision 2001; 51:89-124. (Pubitemid 33635559)
64. Bolland MJ, Jackson R, Gamble GD, Grey A. Discrepancies in predicted fracture risk in elderly people. BMJ 2013; 346:e8669.
65. Gigerenzer G, Gaissmaier W, Kurz-Milcke E, et al. Helping doctors and patients to make sense of health statistics. Psychol Sci Public Interest 2007; 8:53-96.
66. Hoffrage U, Lindsey S, Hertwig R, Gigerenzer G. Medicine. Communicating statistical information. Science 2000; 290:2261-2262.
67. Fagerlin A, Zikmund-Fisher BJ, Ubel PA. Helping patients decide: ten steps to better risk communication. J Natl Cancer Inst 2011; 103:1436-1443.
68. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318:1728-1733.
69. Hudson B, Toop L, Mangin D, Pearson J. Risk communication methods in hip fracture prevention: a randomised trial in primary care. Br J Gen Pract 2011; 61:e469-e476.